Results 111 to 120 of about 304,324 (330)

Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies

Arthritis &Rheumatology, EarlyView.
Objective This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials. Methods Patients were randomized to voclosporin or placebo treatment for up to 3 years; all patients received mycophenolate mofetil and low‐dose glucocorticoids.
Brad H. Rovin, Clarissa Cassol, Samir V. Parikh, Amit Saxena, Neil Solomons, Vanessa Birardi, Ernie Yap, Clint W. Abner, David R. W. Jayne, Robert B. Huizinga   +9 more
wiley   +1 more source

LP-113 Systemic lupus erythematosus induced by experimental therapy with a combination of monoclonal antibodies against the sars-cov2 surface s-protein

Lupus Science and Medicine, 2023
Mariia Aristova, Tatiana Popkova, Tatiana Panafidina, Anna Misiyuk, Magomed Kurbanmagomedov   +4 more
doaj   +1 more source

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus

Clinics, 2012
OBJECTIVE: To determine the serum levels of interferon alpha in childhood-onset systemic lupus erythematosus patients, their first-degree relatives and healthy controls and to evaluate the associations between serum interferon alpha and disease activity,
Mariana Postal, Nailu Angélica Sinicato, Karina Oliveira Peliçari, Roberto Marini, Lilian Tereza Lavras Costallat, Simone Appenzeller   +5 more
doaj  

"Unexplained" Dyspnoea and Shrinking Lungs in Systemic Lupus Erythematosus [PDF]

, 1965
B I Hoffbrand, Elmar Beck
openalex   +1 more source

Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective The presence of antinuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti–double‐stranded DNA (anti‐dsDNA) is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA ...
Hugo J. van Dooren, Mieke van Schaik, Annemarie L. Dorjée, Eline J. Arends, Meggan Mackay, Laura Cooney, David A. Fox, David Wofsy, Dawn Smilek, Cynthia Aranow, Maria Dall'Era, Tom W. J. Huizinga, Cees van Kooten, René E. M. Toes, Betty Diamond, Y. K. Onno Teng, Jolien Suurmond   +16 more
wiley   +1 more source

LP-203 The new markers of systemic lupus erythematosus activity: focus on interleukin (IL)-1b and soluble IL-2 receptor

Lupus Science and Medicine, 2023
Mariia Aristova, Tatyana Panafidina, Yulia Gorbunova, Anastasiya Avdeeva, Tatyana Popkova   +4 more
doaj   +1 more source

Activin A–Activated ALK4 Induces Pathogenic Th17‐Involved Endothelial–Mesenchymal Transition in Systemic Lupus Erythematosus–Associated Pulmonary Arterial Hypertension

Arthritis &Rheumatology, EarlyView.
Objective Autoimmune diseases, such as systemic lupus erythematosus (SLE), are associated with pulmonary arterial hypertension (PAH), a condition that can lead to heart failure. However, whether T cells also contribute to the occurrence of PAH in SLE has not been clarified.
Shuliang Jing, Junyan Qian, Hongjie Ying, Pei Mao, Mingxin Yao, Zhihong Wu, Harm J. Bogaard, Lie Wang, Mengtao Li, Jun Yang   +9 more
wiley   +1 more source

LP-126 The infectious complication in multitarget therapy of class V lupus nephritis: a case report

Lupus Science and Medicine, 2023
Anastasiia Shumilova, Tatiana Popkova, Tatiana Panafidina, Aleksandr Lila   +3 more
doaj   +1 more source

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

Arthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek, Virginie Gonzalez, Lucie Beaudoin, Noémie Sénot, Corinne Miceli‐Richard, Yannick Allanore, Agnès Lehuen, Jerôme Avouac   +7 more
wiley   +1 more source

LP-048 Characteristics and clinical outcome of incomplete systemic lupus erythematosus

Lupus Science and Medicine, 2023
Anastasiia Shumilova, Evgeniy Nasonov, Yulia Gorbunova, Tatiana Popkova, Tatiana Panafidina, Liubov Kondrateva, Alexandr Lila   +6 more
doaj   +1 more source